Storax Attenuates Cardiac Fibrosis following Acute Myocardial Infarction in Rats via Suppression of AT1R–Ankrd1–P53 Signaling Pathway

Myocardial fibrosis following acute myocardial infarction (AMI) seriously affects the prognosis and survival rate of patients. This study explores the role and regulation mechanism of storax, a commonly used traditional Chinese medicine for treatment of cardiovascular diseases, on myocardial fibrosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Zhuo, Lu, Danni, Yuan, Jianmei, Wang, Liying, Wang, Jiajun, Lei, Ziqin, Liu, Si, Wu, Junjie, Wang, Jian, Huang, Lihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657855/
https://www.ncbi.nlm.nih.gov/pubmed/36361958
http://dx.doi.org/10.3390/ijms232113161
_version_ 1784829800954724352
author Xu, Zhuo
Lu, Danni
Yuan, Jianmei
Wang, Liying
Wang, Jiajun
Lei, Ziqin
Liu, Si
Wu, Junjie
Wang, Jian
Huang, Lihua
author_facet Xu, Zhuo
Lu, Danni
Yuan, Jianmei
Wang, Liying
Wang, Jiajun
Lei, Ziqin
Liu, Si
Wu, Junjie
Wang, Jian
Huang, Lihua
author_sort Xu, Zhuo
collection PubMed
description Myocardial fibrosis following acute myocardial infarction (AMI) seriously affects the prognosis and survival rate of patients. This study explores the role and regulation mechanism of storax, a commonly used traditional Chinese medicine for treatment of cardiovascular diseases, on myocardial fibrosis and cardiac function. The AMI rat model was established by subcutaneous injection of Isoproterenol hydrochloride (ISO). Storax (0.1, 0.2, 0.4 g/kg) was administered by gavage once/d for 7 days. Electrocardiogram, echocardiography, hemodynamic and cardiac enzyme in AMI rats were measured. HE, Masson, immunofluorescence and TUNEL staining were used to observe the degree of pathological damage, fibrosis and cardiomyocyte apoptosis in myocardial tissue, respectively. Expression of AT1R, CARP and their downstream related apoptotic proteins were detected by WB. The results demonstrated that storax could significantly improve cardiac electrophysiology and function, decrease serum cardiac enzyme activity, reduce type I and III collagen contents to improve fibrosis and alleviate myocardial pathological damage and cardiomyocyte apoptosis. It also found that storax can significantly down-regulate expression of AT1R, Ankrd1, P53, P-p53 (ser 15), Bax and cleaved Caspase-3 and up-regulate expression of Mdm2 and Bcl-2. Taken together, these findings indicated that storax effectively protected cardiomyocytes against myocardial fibrosis and cardiac dysfunction by inhibiting the AT1R–Ankrd1–P53 signaling pathway.
format Online
Article
Text
id pubmed-9657855
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96578552022-11-15 Storax Attenuates Cardiac Fibrosis following Acute Myocardial Infarction in Rats via Suppression of AT1R–Ankrd1–P53 Signaling Pathway Xu, Zhuo Lu, Danni Yuan, Jianmei Wang, Liying Wang, Jiajun Lei, Ziqin Liu, Si Wu, Junjie Wang, Jian Huang, Lihua Int J Mol Sci Article Myocardial fibrosis following acute myocardial infarction (AMI) seriously affects the prognosis and survival rate of patients. This study explores the role and regulation mechanism of storax, a commonly used traditional Chinese medicine for treatment of cardiovascular diseases, on myocardial fibrosis and cardiac function. The AMI rat model was established by subcutaneous injection of Isoproterenol hydrochloride (ISO). Storax (0.1, 0.2, 0.4 g/kg) was administered by gavage once/d for 7 days. Electrocardiogram, echocardiography, hemodynamic and cardiac enzyme in AMI rats were measured. HE, Masson, immunofluorescence and TUNEL staining were used to observe the degree of pathological damage, fibrosis and cardiomyocyte apoptosis in myocardial tissue, respectively. Expression of AT1R, CARP and their downstream related apoptotic proteins were detected by WB. The results demonstrated that storax could significantly improve cardiac electrophysiology and function, decrease serum cardiac enzyme activity, reduce type I and III collagen contents to improve fibrosis and alleviate myocardial pathological damage and cardiomyocyte apoptosis. It also found that storax can significantly down-regulate expression of AT1R, Ankrd1, P53, P-p53 (ser 15), Bax and cleaved Caspase-3 and up-regulate expression of Mdm2 and Bcl-2. Taken together, these findings indicated that storax effectively protected cardiomyocytes against myocardial fibrosis and cardiac dysfunction by inhibiting the AT1R–Ankrd1–P53 signaling pathway. MDPI 2022-10-29 /pmc/articles/PMC9657855/ /pubmed/36361958 http://dx.doi.org/10.3390/ijms232113161 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Xu, Zhuo
Lu, Danni
Yuan, Jianmei
Wang, Liying
Wang, Jiajun
Lei, Ziqin
Liu, Si
Wu, Junjie
Wang, Jian
Huang, Lihua
Storax Attenuates Cardiac Fibrosis following Acute Myocardial Infarction in Rats via Suppression of AT1R–Ankrd1–P53 Signaling Pathway
title Storax Attenuates Cardiac Fibrosis following Acute Myocardial Infarction in Rats via Suppression of AT1R–Ankrd1–P53 Signaling Pathway
title_full Storax Attenuates Cardiac Fibrosis following Acute Myocardial Infarction in Rats via Suppression of AT1R–Ankrd1–P53 Signaling Pathway
title_fullStr Storax Attenuates Cardiac Fibrosis following Acute Myocardial Infarction in Rats via Suppression of AT1R–Ankrd1–P53 Signaling Pathway
title_full_unstemmed Storax Attenuates Cardiac Fibrosis following Acute Myocardial Infarction in Rats via Suppression of AT1R–Ankrd1–P53 Signaling Pathway
title_short Storax Attenuates Cardiac Fibrosis following Acute Myocardial Infarction in Rats via Suppression of AT1R–Ankrd1–P53 Signaling Pathway
title_sort storax attenuates cardiac fibrosis following acute myocardial infarction in rats via suppression of at1r–ankrd1–p53 signaling pathway
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657855/
https://www.ncbi.nlm.nih.gov/pubmed/36361958
http://dx.doi.org/10.3390/ijms232113161
work_keys_str_mv AT xuzhuo storaxattenuatescardiacfibrosisfollowingacutemyocardialinfarctioninratsviasuppressionofat1rankrd1p53signalingpathway
AT ludanni storaxattenuatescardiacfibrosisfollowingacutemyocardialinfarctioninratsviasuppressionofat1rankrd1p53signalingpathway
AT yuanjianmei storaxattenuatescardiacfibrosisfollowingacutemyocardialinfarctioninratsviasuppressionofat1rankrd1p53signalingpathway
AT wangliying storaxattenuatescardiacfibrosisfollowingacutemyocardialinfarctioninratsviasuppressionofat1rankrd1p53signalingpathway
AT wangjiajun storaxattenuatescardiacfibrosisfollowingacutemyocardialinfarctioninratsviasuppressionofat1rankrd1p53signalingpathway
AT leiziqin storaxattenuatescardiacfibrosisfollowingacutemyocardialinfarctioninratsviasuppressionofat1rankrd1p53signalingpathway
AT liusi storaxattenuatescardiacfibrosisfollowingacutemyocardialinfarctioninratsviasuppressionofat1rankrd1p53signalingpathway
AT wujunjie storaxattenuatescardiacfibrosisfollowingacutemyocardialinfarctioninratsviasuppressionofat1rankrd1p53signalingpathway
AT wangjian storaxattenuatescardiacfibrosisfollowingacutemyocardialinfarctioninratsviasuppressionofat1rankrd1p53signalingpathway
AT huanglihua storaxattenuatescardiacfibrosisfollowingacutemyocardialinfarctioninratsviasuppressionofat1rankrd1p53signalingpathway